← All companies

CRISPR Therapeutics

Healthcare & Life Sci

Company overview

CRISPR Therapeutics is a biotechnology company that develops gene-editing medicines using CRISPR technology. Its lead product, CASGEVY (exagamglogene autotemcel), is a gene-edited therapy approved for sickle cell disease and beta thalassemia.

Emmanuelle Charpentier, Shaun Foy, and Rodger Novak founded the company in 2013. It trades on Nasdaq as CRSP. CASGEVY received FDA approval for clinical use in December 2023, showing gene-editing science can reach real patients, not just the lab. In 2024 the company made US$37.3 million in revenue, with about 393 employees and roughly 500 people in total across four countries. Historically, the median salary is ~$147,500. CRISPR Therapeutics is a top-tier H-1B sponsor.

Industry
Healthcare & Life Sci
Headquarters
Zug, Switzerland

Filters

Create your account

Create an account to save jobs and track applications.